Cellares raises $257M to fund global expansion as it eyes 2027 IPO
Clinical-stage cell therapy manufacturer Cellares has raised $257 million in a Series D round as it gears up commercially and prepares to go public. Cellares aims to launch its commercial cell therapy...
View ArticleBiopharma Sentiment Index | Q1 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric. After four years of hunkering down, the mood in biopharma turned sharply more...
View ArticleHengrui blazes trail as Chinese drugmakers aspire to go multinational
Jiangsu Hengrui Pharmaceuticals has quietly become a top 25 biopharma company in the world by market value. Once virtually unknown outside of China, the company has made its name overseas via an...
View ArticleIncluded Health launches alternative health plan
Included Health, the virtual care and navigation company, is now offering a health plan for employers. It’s new territory for the startup, and the move puts it in a league with companies such as...
View ArticleEikon seeks $273M IPO with pipeline led by Chinese cancer drugs
A biotech led by former Merck top brass with a pipeline anchored by three cancer drugs linked to Chinese drug developers is pushing ahead with an IPO, even while off its peak valuation. Eikon...
View ArticleHHS seeks to protect drugmakers from violating anti-kickback laws ahead of...
With launch time potentially approaching for TrumpRx, HHS unveiled part of its plan to shield drugmakers from anti-kickback laws to allow them to sell their products on the new direct-to-consumer...
View ArticleFDA suspends two Regenxbio gene therapy trials after patient developed brain...
The FDA has placed studies of two gene therapies from Regenxbio on hold after a five-year-old patient in one of the trials was found to have a brain tumor. The drug regulator's decision is a ...
View ArticleLonza still intends to sell its capsules and health ingredients business
More than a year after Lonza announced it will sell its capsules and health business, the Swiss CDMO said it has yet to finalize the deal with a buyer. A spokesperson said it has multiple ...
View ArticleFDA asks court to pause Louisiana's abortion pill fight
The Trump administration is asking a federal court to halt a case over the abortion pill mifepristone while the FDA undertakes a review of the drug’s safety protocols. An ongoing mifepristone review...
View ArticleOral Rogaine maker Veradermics looks to raise $181M from IPO
Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO. The Connecticut biotech will garner that amount...
View ArticleRound three of IRA negotiations is expected to be ‘manageable’ for pharma
Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS
View ArticleChenMed CEO warns against GLP-1s for seniors
ChenMed CEO Chris Chen said the primary care chain isn’t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to worse health outcomes among its older patients. Speaking...
View ArticleTenpoint gets FDA nod for presbyopia eye drop and $235M
Tenpoint Therapeutics landed an FDA approval for its presbyopia eye drop on Wednesday, entering a tricky commercial landscape for therapeutic alternatives to reading glasses and contacts. In...
View ArticleFlagship's Repertoire gets another autoimmune partner in Lilly
Repertoire Immune Medicines has added a fourth pharmaceutical partner by teaming up with Eli Lilly. The Indianapolis pharma joins Bristol Myers Squibb and Genentech in allying with Repertoire on...
View ArticleSanofi says its €15B dealmaking budget, R&D spend should help ease looming...
Sanofi says it will be able to spend between €14 billion and €15 billion on M&A deals this year while still being able to meet its financial commitments. “It doesn’t mean that we will make ...
View ArticleFollowing Abivax, Formation Bio licenses miR-124 drug from China
The French biotech Abivax was a biotech market standout for 2025. Formation Bio now wants a piece of that success. The privately-held New York pharma startup has licensed a small molecule aimed ...
View ArticleUpdated: Roche predicts its breast cancer pill could become its...
With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Roche’s breast cancer drug giredestrant is sitting pretty. Management...
View ArticlePremise Health to merge with Crossover Health to expand employer clinics
Two companies that run on-site health clinics for employers like Google and Amazon are merging as healthcare costs continue to climb. Advanced primary care company Premise Health is acquiring...
View Article